Table 3.
Multivariable logistic regression analysis of possible variables (P<0.05 in univariate logistic regression analysis) predicting pCR
| P | OR | 95 % CI | |
|---|---|---|---|
| Tumor size | |||
| T1 | 1 | ||
| T2 | 0.186 | 0.576 | 0.255-1.304 |
| T3 | 0.544 | 0.737 | 0.275-1.975 |
| T4 | 0.015 | 0.281 | 0.101-0.779 |
| Hormone receptor status | |||
| Negative | 1 | ||
| Positive | <0.001 | 0.224 | 0.125-0.400 |
| Regimens | |||
| Cyclophosphamide, epirubicin and 5-fluorouracil | 1 | ||
| Cyclophosphamide, epirubicin and 5-fluorouracil followed by paclitaxel or docetaxel and epirubicin | 0.208 | 4.673 | 0.423-51.590 |
| Navelbine and epirubicin | 0.078 | 6.999 | 0.804-60.897 |
| Paclitaxel and carboplatin or paclitaxel and cisplatin | 0.003 | 27.696 | 3.131-245.030 |
| Cycles | |||
| 3-4 | 1 | ||
| 1-2 | 0.500 | 0.579 | 0.118-2.834 |
| 5-6 | 0.217 | 2.338 | 0.606-9.017 |
Abbreviations: pCR pathological complete response, OR odds ratio, CI confidence interval